---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-037652"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:04:16.121539+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CV Sciences FY2023 revenue $16.0M (flat), gross margin improves to 44.3% from 34.2%

## Summary
- Revenue $16.0M for FY2023, flat vs $16.2M in 2022; Q4 revenue $3.8M down 2% YoY.
- Gross margin 44.3% (FY2022: 34.2%); operating income $3.4M vs loss $6.8M, helped by $6.2M payroll tax reversal.
- Cash $1.3M at year-end; cash from operations $2.3M including $2.5M employee retention credit.
- Adjusted EBITDA negative $2.3M in FY2023, improved from negative $6.1M in FY2022.
- Acquired Cultured Foods in Q4 2023; launched new products; #1 hemp extract brand in natural retail per SPINS.

## SEC filing metadata
- accession: 0000950170-24-037652
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/0000950170-24-037652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/cvsi-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-037652
- JSON: https://secwatch.observer/filing/0000950170-24-037652.json
- Plain text: https://secwatch.observer/filing/0000950170-24-037652.txt

## Key facts
- Earnings Releases
  CV Sciences, Inc. reported the fourth quarter of 2023 results: revenue $3.8 million.
  - Period: the fourth quarter of 2023
  - Revenue: $3.8 million
  - Result: reported results
  source text: Revenue of $3.8 million for the fourth quarter 2023 compared to $4.1 million in the third quarter 2023;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/0000950170-24-037652-index.htm
- Earnings Releases
  CV Sciences, Inc. reported fiscal year ended December 31, 2023 results: revenue $16.0 million.
  - Period: fiscal year ended December 31, 2023
  - Revenue: $16.0 million
  - Result: reported results
  source text: Generated revenue of $16.0 million for fiscal 2023 compared to $16.2 million for 2022;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/0000950170-24-037652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.